Answers are grounded in this paper and cite their sources.
cAMP signaling plays an essential role in modulating the proliferation of different cell types, including cancer cells. Until now, the regulation of this pathway was restricted to the transmembrane class of adenylyl cyclases. In this study, significant overexpression of soluble adenylyl cyclase (sAC), an alternative source of cAMP, was found in human prostate carcinoma, and therefore, the contribution of this cyclase was investigated in the prostate carcinoma cell lines LNCaP and PC3. Suppression of sAC activity by treatment with the sAC-specific inhibitor KH7 or by sAC-specific knockdown mediated by siRNA or shRNA transfection prevented the proliferation of prostate carcinoma cells, led to lactate dehydrogenase release, and induced apoptosis. Cell cycle analysis revealed a significant rise in the G 2 phase population 12 h after sAC inhibition, which was accompanied by the down-regulation of cyclin B 1 and CDK1. sAC-dependent regulation of proliferation involves the EPAC/Rap1/B-Raf signaling pathway. In contrast, protein kinase A does not play a role. In conclusion, this study suggests a novel sAC-dependent signaling pathway that controls the proliferation of prostate carcinoma cells. Background: Soluble adenylyl cyclase (sAC) may be an alternative intracellular localized source of cAMP controlling proliferation. Results: sAC is overexpressed in prostate carcinoma, and inhibition of sAC leads to cell cycle arrest. Conclusion: sAC controls proliferation of prostate carcinoma cells. Significance: sAC represents a novel pathway promoting proliferation in cancer cells and is a promising target for prostate cancer treatment.
No takes yet. Share an insight, caveat, or question.
Flacke et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: